Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (3539)	4/23/2001 8:42:46 AM
From: Mark Bong	Respond to of 52153

George, during the last Biogen CC, Bert Adleman, their scientific director did say that subcutaneous injections demonstrated the same efficacy as IV for psoriasis during Phase III. This is the first time that I heard a statement out of Biogen regarding the successful delivery through subcutaneous injections. This probably tips the balance in favor of BGEN. In addition, BGEN indicated that through phase III the safety profile of Amevive was very clean. Mark